SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549


                                   SCHEDULE TO

        Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the
                        Securities Exchange Act of 1934
                                (Amendment No. 5)

                           Utah Medical Products, Inc.
                           ---------------------------
                                (Name of Issuer)

                      Utah Medical Products, Inc. (Issuer)
                      ------------------------------------
                            (Name of Filing Persons)

                     Common Stock, Par Value $.01 Per Share
                     --------------------------------------
                         (Title of Class of Securities)

                                    917488108
                      -------------------------------------
                      (Cusip Number of Class of Securities)

                                Kevin L. Cornwell
                                Chairman and CEO
                           Utah Medical Products, Inc.
                               7043 South 300 West
                               Midvale, Utah 84047
                                 (801-566-1200)
        ---------------------------------------------------------------
          (Name, address and telephone numbers of person authorized to
        receive notices and communications on behalf of filing persons)

                            CALCULATION OF FILING FEE

 Transaction Valuation*                                  Amount of Filing Fee
     $8,200,000                                                 $1,640

*  Calculated  solely for the  purpose of  determining  the amount of the filing
   fee,  based on the purchase of 1,000,000  shares of Common  Stock,  par value
   $.01 per share, at the tender offer price of $8.20 per share.

[X]  Check  the  box if any  part  of the  fee is  offset  as  provided  by Rule
     0-11(a)(2)  and  identify  the  filing  with which the  offsetting  fee was
     previously  paid.  Identify the previous filing by  registration  statement
     number, or the Form or Schedule and the date of its filing.

Amount Previously Paid:  $1,640
Filing Party:  Utah Medical Products, Inc.
Form or Registration No.:  Amendment No. 1 to Schedule TO
Date Filed:  August 18, 2000

[ ]  Check the box if the filing relates solely to preliminary  communications
     made before the commencement of a tender offer.

Check the  appropriate  boxes below to designate  any  transaction  to which the
statement relates:

[ ]      third-party tender offer subject to Rule 14d-1.
[x]      issuer tender offer subject to Rule 13e-4.
[ ]      going-private transaction subject to Rule 13e-3
[ ]      amendment to Schedule 13D under Rule 13d-2

Check the following box if the filing is a final amendment reporting the results
of the tender offer: [x]



     This  Amendment No. 5 to the Tender Offer  Statement on Schedule TO relates
to the tender offer by Utah Medical Products,  Inc., a Utah corporation  ("UTMD"
or the "Company"), to purchase 1,000,000 shares, or such lesser number of shares
as are validly  tendered and not withdrawn,  of its Common Stock, par value $.01
per share, including the associated common stock purchase rights issued pursuant
to the Rights  Agreement,  dated as of October 28,  1994,  between  Utah Medical
Products, Inc. and Registrar and Transfer Company as Rights Agent, at a price of
$8.20 per Share,  upon the terms and subject to the  conditions set forth in the
Offer to Purchase  dated August 18, 2000 (the "Offer to  Purchase"),  and in the
related Letter of Transmittal  which,  as they may be amended from time to time,
together  constitute  the  "Offer,"  copies of which  were  previously  filed on
Amendment  No.  1 to  the  Schedule  TO  as  Exhibit  (a)(1)(A)  and  (a)(1)(B),
respectively. This Amendment No. 5 to the Schedule TO is intended to satisfy the
reporting  requirements  of Rule  13e-4(c)(1) of the Securities  Exchange Act of
1934, as amended.

     The Offer expired at 5:00 p.m.,  New York City time,  on Friday,  September
15, 2000. In accordance with the terms of the Offer,  UTMD accepted for purchase
1,118,944  Shares.  The final proration  factor for the Offer is 69.0%.  Odd Lot
Shares of 3,272 were purchased prior to proration. The Offer was oversubscribed,
with 1,608,225 Shares properly tendered and not properly  withdrawn  pursuant to
the Offer.  In  addition  to the  1,000,000  Shares  subject to the Offer,  UTMD
exercised its option to purchase an additional 110,720 Shares,  representing not
more than 2% of its outstanding Shares, and accepted all Shares duly tendered by
any stockholder who tendered all Shares owned  beneficially and who, as a result
of proration, would then own beneficially an aggregate of fewer than 100 shares.
The number of such Shares was 8,224. The 1,118,944 Shares purchased  pursuant to
the Offer represented about 18.2% of the outstanding Shares immediately prior to
the Offer.  Following  the  purchase of the Shares  accepted  in the Offer,  the
Company has 5,026,803 Shares outstanding.

     Payment for Shares  accepted,  and the return of all other Shares tendered,
commenced on September 28, 2000.


                                    SIGNATURE

         After due inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.


                                        UTAH MEDICAL PRODUCTS, INC.


                                   By:      /s/ KEVIN L. CORNWELL
                                            ------------------------------------
                                   Name:    Kevin L. Cornwell
                                   Title:   Chairman and Chief Executive Officer

Dated: September 28, 2000